D-AP5 (D-APV) is a selective and competitiveNMDA receptorantagonist with aK_dof 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors^[1][2].

NMDA^[1]

D-AP5 is a NMDA receptor antagonist. Chronic intraventricular infusion of D-AP5 causes a parallel dose-dependent impairment of spatial learning and long-term potentiation (LTP)in vivo. Intracerebral concentrations of D-AP5 fail to induce any measurable sensorimotor disturbance when spatial learning is prevented^[2].
D-AP5 infusion is associated with a progressive reduction in swim speed over trials. D-AP5 causes sensorimotor disturbances in the spatial task, but these gradually worsened as the animals fail to learn. Rats treated with D-AP5 show a delay-dependent deficit in spatial memory in the delayed matching-to-place protocol for the water maze^[3].

197.13

Solid

C₅H₁₂NO₅P

79055-68-8

Room temperature in continental US; may vary elsewhere.

H₂O : 27.78 mg/mL(140.92 mM;Need ultrasonic)

DMSO :< 1 mg/mL (ultrasonic;warming;heat to 60℃)(insoluble or slightly soluble)

Ethanol :< 1 mg/mL (ultrasonic)(insoluble)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： PBS

  Solubility: 100 mg/mL (507.28 mM); Clear solution; Need ultrasonic